drugset / Trial / NCT05224089

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

NCT05224089 ↗

Phase 4 Recruiting 114 enrolled Hartford Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy procedures.

Timeline

Start
2022-04-27
Primary completion
2025-11
Completion
2026-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 150 mg Other
Subject Bupivacaine Other / unclassified 200 mg Other
Subject Bupivacaine Other / unclassified 266 mg Other
Background Dexamethasone Small molecule 5 mg Other
Background Epinephrine Other / unclassified 300 ug Other

Indications